Robin Foà MD, EHA 2019 – CAR-T cells in the treatment of haematological malignancies
At the EHA annual meeting in Amsterdam, Editorial Board member Robin Foà joins us to discuss the latest initiatives surrounding CAR-T cells and their use in the treatment of haematological malignancies.
Questions
1. What are the major challenges to incorporating CAR-T cells into clinical practice? (0:06)
2. Where are CAR-T cells likely to fit into the treatment paradigm for haematological malignancies? (1:46)
3. Why is it important to quantify minimal residual disease in haematological malignancies? (2:57)
4. How have new molecular technologies impacted on the evaluation of minimal residual disease? (4:30)
5. How will this breakthrough impact future clinical practice? (5:48)
Professor Robin Foà has no conflicts of interest in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
